The frequency of genotypes in stable anticoagulated patients classified by stable anticoagulation dose
| Gene polymorphism | Genotype | Stable | Low dose | Intermediate dose | High dose | p-value |
|---|---|---|---|---|---|---|
| VKORC1*2 (rs9923231) | CC | 13 | 0 | 13 | 1 | 0.280 |
| CT | 17 | 1 | 15 | 1 | ||
| TT | 3 | 1 | 2 | 0 | ||
| CYP2C9*2 (rs1799853) | CC (WT) | 21 | 1 | 18 | 2 | 0.498 |
| CT | 13 | 1 | 12 | 0 | ||
| CYP2C9*3 (rs1057910) | AA (WT) | 29 | 1 | 27 | 1 | 0.047 |
| AC | 4 | 1 | 2 | 1 | ||
| CYP4F2*3 (rs2108622) | CC (WT) | 15 | 1 | 14 | 0 | 0.685 |
| CT | 17 | 1 | 14 | 2 | ||
| TT | 2 | 0 | 2 | 0 | ||
| CYP2C19*17 (rs12248560) | GG (WT) | 26 | 2 | 22 | 2 | 0.542 |
| GA | 7 | 0 | 7 | 0 | ||
| ABCB1 C3435T (rs1045642) | CC (WT) | 9 | 1 | 8 | 0 | 0.430 |
| CT | 15 | 1 | 12 | 2 | ||
| TT | 10 | 0 | 10 | 0 | ||
(High dose: >28 mg/week; Intermediate dose: 7–28 mg/week; Low dose: <7 mg/week)